U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
Diagnostic and Interventional Cardiology,
June 20, 2023 — AGEPHA Pharma USA, LLC, announced that, following a Priority Review, the U.S.
U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
Spoke,
LODOCO® (colchicine, 0.5 mg tablet) Reduces Cardiac Event Risk in Adult Patients with Established Atherosclerotic…
U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
Morning Star,
LODOCO® (colchicine, 0.5 mg tablet) Reduces Cardiac Event Risk in Adult Patients with Established Atherosclerotic…
U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
Yahoo! Finance USA,
LODOCO® (colchicine, 0.5 mg tablet) Reduces Cardiac Event Risk in Adult Patients with Established Atherosclerotic…